Primary Progressive Multiple Sclerosis Clinical Trials 2023

What are the top hospitals conducting primary progressive multiple sclerosis research?

In the realm of primary progressive multiple sclerosis (PPMS) clinical trials, several hospitals have emerged as leaders in research and innovation. Located in Cleveland, Ohio, the renowned Cleveland Clinic stands out with six ongoing PPMS trials and a total of four completed trials dedicated to this unique form of multiple sclerosis. Their first recorded PPMS trial took place in 2013, marking a significant milestone in their commitment to finding effective treatments for this condition. On the west coast, the University of California San Francisco is making substantial contributions with five active PPMS trials and three past studies that delve into this complex disease. In 2016, they embarked on their initial journey into PPMS research.

Meanwhile, at Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis in Owosso—a lesser-known but vital player—researchers are currently engaged in five active clinical trials focused on PPMS. Although they have conducted only two previous studies thus far since debuting their first trial dedicated to primary progressive multiple sclerosis just last year in 2020, they are rapidly establishing themselves as an important institution within the field.

Notably contributing to advances from outside traditional hospital settings is Novartis Investigative Site located in Saint Louis where researchers actively conduct four primary progressive MS investigations while having accomplished similar tasks throughpast thirteen years by conducting experiments around this matter from starting it off back at2008.Also present among these esteemed institutions is Johns Hopkins University situatedin Baltimore performingfour current primary progressive MS tests while making substantial strides with one prior study initiated recently just couple years ago during 2018.

These top hospitals and research facilities represent hope not only for those living with primary progressive multiple sclerosis but also underscore the collective dedication towards unraveling its complexities.They remind us that amidst medical challenges there are professionals relentlessly workingto drive progress forwardbringing new possibilities closerfor individuals affected bythis chronic neurological condition

Which are the best cities for primary progressive multiple sclerosis clinical trials?

When it comes to primary progressive multiple sclerosis clinical trials, several cities emerge as key hubs for research and development. Philadelphia, Pennsylvania leads the way with 23 active trials investigating various treatments such as RPC-1063, Ocrelizumab, and Cohort B. Saint Louis, Missouri closely follows with 19 ongoing studies focusing on interventions like RPC-1063 and Nivolumab. New york, New York also plays a significant role with 18 active trials exploring options such as Ocrelizumab and Cohort B. Phoenix, Arizona and Detroit, Michigan stand out as well with 17 and 16 active trials respectively examining potential breakthroughs in treatment methods including Ocrelizumab and RPC-1063. In these cities across different regions of the United States, individuals living with primary progressive multiple sclerosis have access to cutting-edge clinical trials that drive advancements in care for this challenging condition.

Which are the top treatments for primary progressive multiple sclerosis being explored in clinical trials?

Clinical trials are paving the way for advancements in treating primary progressive multiple sclerosis (PPMS). Leading the charge is ocrelizumab, a treatment under investigation in 14 active trials. Since its introduction in 2011, it has been included in nine all-time clinical trials aimed at tackling PPMS. Another promising contender is fenebrutinib, currently being studied in three ongoing trials after its listing in 2020. Autologous hematopoietic stem cell transplantation rounds out the list with two active studies since its debut as a treatment option for PPMS patients back in 2019. These innovative approaches offer hope and potential breakthroughs for those living with this challenging form of multiple sclerosis.

What are the most recent clinical trials for primary progressive multiple sclerosis?

Exciting advancements are being made in the field of primary progressive multiple sclerosis (PPMS) through recent clinical trials. One innovative approach is transcranial direct current stimulation, which has shown promise in early and intermediate stages of PPMS treatment. Another potential therapy is Clemastine Fumarate, currently undergoing Phase 1 and Phase 2 trials to evaluate its efficacy in managing PPMS symptoms. Additionally, a study investigating BIIB091 combined with DRF Standard Dose aims to uncover new possibilities for treating this challenging condition. Notably, Ocrelizumab SC is also being studied as a potential treatment option for PPMS patients in Phase 3 trials. These groundbreaking clinical trials offer hope to individuals living with primary progressive multiple sclerosis by potentially improving their quality of life and slowing disease progression.

What primary progressive multiple sclerosis clinical trials were recently completed?

Several recent clinical trials have made significant strides in the field of primary progressive multiple sclerosis (PPMS), offering hope for patients battling this challenging condition. In June 2022, the University of Utah concluded a trial investigating the use of MRI Brain and Cervical Spine to better understand and manage PPMS. Furthermore, Johns Hopkins University completed a trial in June 2018 that explored the potential benefits of Tauroursodeoxycholic Acid as a treatment option for PPMS. These advancements underscore ongoing efforts to improve our understanding and develop effective interventions for individuals with primary progressive multiple sclerosis.